Dinámica de la Respuesta Inmunitaria Antitumoral
IT-LIVE
Centro Nacional de Investigaciones Cardiovasculares Carlos III
Madrid, EspañaPublicaciones en colaboración con investigadores/as de Centro Nacional de Investigaciones Cardiovasculares Carlos III (7)
2022
-
Depletion of Conventional Type-1 Dendritic Cells in Established Tumors Suppresses Immunotherapy Efficacy
Cancer research, Vol. 82, Núm. 23, pp. 4373-4385
2019
-
The clinical application of cancer immunotherapy based on naturally circulating dendritic cells
Journal for ImmunoTherapy of Cancer, Vol. 7, Núm. 1
2018
-
Intratumoral immunotherapy with XCL1 and sFlt3L encoded in recombinant semliki forest virus–derived vectors fosters dendritic cell–mediated t-cell cross-priming
Cancer Research, Vol. 78, Núm. 23, pp. 6643-6654
-
Mitochondrial morphological and functional reprogramming following CD137 (4-1BB) Costimulation
Cancer Immunology Research, Vol. 6, Núm. 7, pp. 798-811
2017
-
Antigen cross-presentation and T-cell cross-priming in cancer immunology and immunotherapy
Annals of Oncology, Vol. 28, pp. xii44-xii55
-
CD69 is a direct HIF-1α target gene in hypoxia as a mechanism enhancing expression on tumor-infiltrating T lymphocytes
OncoImmunology, Vol. 6, Núm. 4
2011
-
Agonist anti-CD137 mAb act on tumor endothelial cells to enhance recruitment of activated T lymphocytes
Cancer Research, Vol. 71, Núm. 3, pp. 801-811